|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
61,398,000 |
Market
Cap: |
389.26(M) |
Last
Volume: |
1,040,465 |
Avg
Vol: |
716,466 |
52
Week Range: |
$3.38 - $6.66 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 803 |
Guru Rank Value : 1 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Vanda Pharmaceuticals is a biopharmaceutical company. Co.'s commercial portfolio is comprised of two products, HETLIOZ® for the treatment of Non-24 Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome and Fanapt® for the treatment of schizophrenia. In addition, Co. has a number of drugs in development, including: Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist, for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia; and VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
121,098 |
133,534 |
375,216 |
Total Sell Value |
$0 |
$513,345 |
$588,387 |
$2,607,605 |
Total People Sold |
0 |
5 |
6 |
6 |
Total Sell Transactions |
0 |
10 |
13 |
31 |
End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Dugan Richard W |
Director |
|
2023-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
17,307 |
97,700 |
|
- |
|
Chrousos Phaedra |
Director |
|
2023-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
17,307 |
42,238 |
|
- |
|
Ward Anne Sempowski |
Director |
|
2023-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
17,307 |
39,313 |
|
- |
|
Mitchell Stephen Ray |
Director |
|
2023-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
17,307 |
35,828 |
|
- |
|
Honore Tage |
Director |
|
2023-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
26,408 |
26,408 |
|
- |
|
Birznieks Gunther |
SVP, Business Development |
|
2023-03-03 |
4 |
S |
$6.26 |
$51,791 |
D/D |
(8,268) |
205,980 |
|
5% |
|
Wijkstrom Joakim |
SVP, Chief Marketing Officer |
|
2023-03-03 |
4 |
S |
$6.32 |
$25,994 |
D/D |
(4,113) |
117,540 |
|
5% |
|
Polymeropoulos Mihael Hristos |
President and CEOChairman of t |
|
2023-03-03 |
4 |
S |
$6.25 |
$140,876 |
D/D |
(22,538) |
1,476,902 |
|
5% |
|
Moran Kevin Patrick |
SVP, CFO & Treasurer |
|
2023-03-03 |
4 |
S |
$6.28 |
$37,499 |
D/D |
(5,968) |
138,926 |
|
5% |
|
Williams Timothy |
SVP & General Counsel |
|
2023-03-03 |
4 |
S |
$6.25 |
$51,887 |
D/D |
(8,301) |
103,513 |
|
5% |
|
Birznieks Gunther |
SVP, Business Development |
|
2023-03-02 |
4 |
S |
$6.20 |
$52,793 |
D/D |
(8,509) |
214,248 |
|
1% |
|
Wijkstrom Joakim |
SVP, Chief Marketing Officer |
|
2023-03-02 |
4 |
S |
$6.23 |
$48,123 |
D/D |
(7,720) |
121,653 |
|
1% |
|
Polymeropoulos Mihael Hristos |
President and CEOChairman of t |
|
2023-03-02 |
4 |
S |
$6.23 |
$139,718 |
D/D |
(22,426) |
1,499,440 |
|
1% |
|
Moran Kevin Patrick |
SVP, CFO & Treasurer |
|
2023-03-02 |
4 |
S |
$6.26 |
$49,846 |
D/D |
(7,966) |
144,894 |
|
1% |
|
Williams Timothy |
SVP & General Counsel |
|
2023-03-02 |
4 |
S |
$6.24 |
$52,685 |
D/D |
(8,437) |
111,814 |
|
1% |
|
Moran Kevin Patrick |
SVP, CFO & Treasurer |
|
2023-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
32,700 |
152,860 |
|
- |
|
Polymeropoulos Mihael Hristos |
President and CEOChairman of t |
|
2023-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
115,000 |
1,521,866 |
|
- |
|
Wijkstrom Joakim |
SVP, Chief Marketing Officer |
|
2023-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
32,700 |
129,373 |
|
- |
|
Williams Timothy |
SVP & General Counsel |
|
2023-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
32,700 |
120,251 |
|
- |
|
Birznieks Gunther |
SVP, Business Development |
|
2023-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
32,700 |
222,757 |
|
- |
|
Williams Timothy |
SVP & General Counsel |
|
2022-12-15 |
4 |
S |
$7.01 |
$56,070 |
D/D |
(8,000) |
87,551 |
|
11% |
|
Polymeropoulos Mihael Hristos |
President and CEOChairman of t |
|
2022-12-06 |
4 |
S |
$10.61 |
$512,082 |
D/D |
(48,250) |
1,406,866 |
|
42% |
|
Polymeropoulos Mihael Hristos |
President and CEOChairman of t |
|
2022-12-06 |
4 |
OE |
$3.12 |
$235,139 |
D/D |
75,365 |
1,455,116 |
|
- |
|
Moran Kevin Patrick |
SVP, CFO & Treasurer |
|
2022-12-06 |
4 |
S |
$10.61 |
$50,827 |
D/D |
(4,792) |
120,160 |
|
42% |
|
Moran Kevin Patrick |
SVP, CFO & Treasurer |
|
2022-12-06 |
4 |
OE |
$3.12 |
$23,400 |
D/D |
7,500 |
124,952 |
|
- |
|
277 Records found
|
|
Page 2 of 12 |
|
|